Extrait

To collect further basic safety data on patients with advanced or metastatic malignancies treated with enzastaurin.

Critère d'inclusion

• Have a histologic or cytologic diagnosis of advanced or metastatic malignancies for which no life-prolonging therapy exists and have been previously enrolled and completed therapy in an enzastaurin clinical pharmacology and biopharmaceutics study

Liens

• euctr
• ictrp